Tina Bhutani-Jacques, MD, explored how disease location, prior treatment response, and patient preference shape topical treatment decisions across 3 plaque psoriasis cases.
|Articles|August 10, 2018
- Dermatology Times, August 2019 (Vol. 39, No. 8)
- Volume 39
- Issue No. 8
Comprehensive psoriasis management
Author(s)Dermatology Times Staff
The August issue of Dermatology Times includes a supplement edition that focuses on a patient-centered approach in psoriasis management, including an article on the importance of longer consults in the doctor's office and recommendations for individualized therapy. Read more here.
Advertisement
The August issue of Dermatology Times includes a supplement edition that focuses on a patient-centered approach in psoriasis management, including an article on the importance of longer consults in the doctor's office and recommendations for individualized therapy.
Articles in this issue
about 8 years ago
Communication in the era of patient-centered careabout 8 years ago
Dermatology training for nurses and PAsabout 8 years ago
Is it time to regulate probiotics in cosmetics?about 8 years ago
11 steps to improving doctor-patient communicationabout 8 years ago
Language used in medical records can stigmatize patients for yearsabout 8 years ago
EC moves forward with new PsA treatmentabout 8 years ago
Make patient-centered work in practiceabout 8 years ago
New AAD cSCC treatment guidelinesabout 8 years ago
Emotional burden of skin conditions may be rooted in physiologyabout 8 years ago
Outlook for new botulinum toxins in the U.S. marketAdvertisement
Related to this article
Two-year oral IL-23 data, GLP-1 biomarker findings, and a nonsurgical option for superficial basal cell carcinoma headline the sessions covered in Las Vegas.
In a retrospective study of 393 patients, 51.9% had at least 1 abnormal LFT during follow-up, but only 1.1% had elevations above 3 times the upper limit of normal.
Patients with plaque psoriasis treated with roflumilast cream or foam reported greater improvements in sexual function and relationships vs vehicle, including those with genital involvement at baseline.
By week 36, combination therapy altered 482 proteins and 467 genes vs 140 and 16 with ixekizumab alone in exploratory TOGETHER-PsO data.
Advertisement
Advertisement
Trending on Dermatology Times
1
AAD, HS Foundation Issue First Joint Hidradenitis Suppurativa Guidelines
2
Dupilumab Associated With Lower Atopic March Risk in Pediatric Atopic Dermatitis
3
Nonsteroidal Topicals Guide Special-Site Psoriasis Treatment Decisions
4
Severity, Response Timing, and Lab Monitoring in Alopecia Areata Care
5